[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvU8UhwVssD7gZH-nr0tmEqZ03shVKxDRlisXbEpPBhI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":69,"rows":76},"King's College Hospital NHS Trust",[4],163,false,40,11,174554,12,127,[14,17,19,21,23,26,28,30],{"name":15,"count":16},"Leukemia, Myeloid, Acute",5,{"name":18,"count":16},"Myelodysplastic Syndromes",{"name":20,"count":16},"Chronic Kidney Diseases",{"name":22,"count":16},"Obesity",{"name":24,"count":25},"Diverticular Disease",4,{"name":27,"count":25},"Cardiovascular Diseases",{"name":29,"count":25},"Dyspnea",{"name":31,"count":32},"Stroke",3,[34,39,44,49,54,59,64],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06053671","Mos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue)","2025-04-08","Blood and nasal swab sampling",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06469528","ESCALATion of Medical Therapy Following Multimodality Plaque Evaluation in High-risk Chronic Coronary Syndromes","2025-10-05","Colchicine 0.5 MG",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06234592","The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock","2026-01","Angiotensin II",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05872698","Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial.","2026-12","Carvedilol",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06572215","DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve","2027-12-31","Dapagliflozin",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07558135","The ARISE Trial Compares Whether Giving Routine Steroid Replacement or Using Targeted Blood Tests to Guide Replacement Better Protects Certain Patients From Adrenal Insufficiency After the Removal of a Diseased Adrenal Gland.","2028-09","Empirical Hydrocortisone Protocol",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT04663750","Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).","2028-12","Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until month 12",[70,71,72,73,74,75],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[77,118,144,162,180,203,225,243,263,288,306,324,347,375,402,428,446,473,497,519,546,574,600,626,655,673,698,724,749,794,829,851,869,887,912,938,956,982,1000,1018,1036,1054,1072,1090,1116,1134,1152,1197,1215,1241,1267,1294],{"intervention":53,"totalTrials":78,"cells":79},2,{"EARLY_PHASE1":80,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":89,"NA":116},{"trials":81,"activeCount":82},[],0,{"trials":84,"activeCount":82},[],{"trials":86,"activeCount":82},[],{"trials":88,"activeCount":82},[],{"trials":90,"activeCount":115,"soonestReadout":52},[91,104],{"nctId":92,"briefTitle":93,"status":94,"phases":95,"primaryCompletion":96,"completion":97,"start":98,"enrollment":99,"conditions":100,"interventions":103},"NCT03776955","Beta-blockers for Oesophageal Varices","UNKNOWN",[74],"2024-09","2024-12","2019-06-17",1200,[101,102],"Cirrhoses, Liver","Oesophageal Varices",[53],{"nctId":50,"briefTitle":51,"status":105,"phases":106,"primaryCompletion":52,"completion":52,"start":107,"enrollment":108,"conditions":109,"interventions":114},"ACTIVE_NOT_RECRUITING",[74],"2019-04-01",763,[110,111,112,113],"Cirrhosis, Liver","Portal Hypertension","Variceal Hemorrhage","Varices, Esophageal",[53],1,{"trials":117,"activeCount":82},[],{"intervention":68,"totalTrials":115,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":140,"NA":142},{"trials":121,"activeCount":82},[],{"trials":123,"activeCount":82},[],{"trials":125,"activeCount":82},[],{"trials":127,"activeCount":115,"soonestReadout":67},[128],{"nctId":65,"briefTitle":66,"status":129,"phases":130,"primaryCompletion":67,"completion":67,"start":131,"enrollment":132,"conditions":133,"interventions":137},"RECRUITING",[73],"2021-04-16",210,[134,135,136],"Eye Diseases","Macular Degeneration, Wet","Sub-Macular Hemorrhage",[68,138,139],"subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls","Intravitreal 20% sulfahexafluoride (SF6) gas tamponade",{"trials":141,"activeCount":82},[],{"trials":143,"activeCount":82},[],{"intervention":138,"totalTrials":115,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":158,"NA":160},{"trials":147,"activeCount":82},[],{"trials":149,"activeCount":82},[],{"trials":151,"activeCount":82},[],{"trials":153,"activeCount":115,"soonestReadout":67},[154],{"nctId":65,"briefTitle":66,"status":129,"phases":155,"primaryCompletion":67,"completion":67,"start":131,"enrollment":132,"conditions":156,"interventions":157},[73],[134,135,136],[68,138,139],{"trials":159,"activeCount":82},[],{"trials":161,"activeCount":82},[],{"intervention":139,"totalTrials":115,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":176,"NA":178},{"trials":165,"activeCount":82},[],{"trials":167,"activeCount":82},[],{"trials":169,"activeCount":82},[],{"trials":171,"activeCount":115,"soonestReadout":67},[172],{"nctId":65,"briefTitle":66,"status":129,"phases":173,"primaryCompletion":67,"completion":67,"start":131,"enrollment":132,"conditions":174,"interventions":175},[73],[134,135,136],[68,138,139],{"trials":177,"activeCount":82},[],{"trials":179,"activeCount":82},[],{"intervention":43,"totalTrials":115,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":199,"NA":201},{"trials":183,"activeCount":82},[],{"trials":185,"activeCount":82},[],{"trials":187,"activeCount":82},[],{"trials":189,"activeCount":115,"soonestReadout":42},[190],{"nctId":40,"briefTitle":41,"status":191,"phases":192,"primaryCompletion":42,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NOT_YET_RECRUITING",[73],"2026-10-05","2024-06-24",50,[197],"Coronary Artery Disease",[43],{"trials":200,"activeCount":82},[],{"trials":202,"activeCount":82},[],{"intervention":63,"totalTrials":115,"cells":204},{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":206,"activeCount":82},[],{"trials":208,"activeCount":82},[],{"trials":210,"activeCount":82},[],{"trials":212,"activeCount":82},[],{"trials":214,"activeCount":82},[],{"trials":216,"activeCount":115,"soonestReadout":62},[217],{"nctId":60,"briefTitle":61,"status":191,"phases":218,"primaryCompletion":62,"completion":67,"start":219,"enrollment":220,"conditions":221,"interventions":223},[75],"2026-09",96,[222],"Adrenal Gland Disease",[63,224],"Targeted Treatment Protocol",{"intervention":224,"totalTrials":115,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":237},{"trials":228,"activeCount":82},[],{"trials":230,"activeCount":82},[],{"trials":232,"activeCount":82},[],{"trials":234,"activeCount":82},[],{"trials":236,"activeCount":82},[],{"trials":238,"activeCount":115,"soonestReadout":62},[239],{"nctId":60,"briefTitle":61,"status":191,"phases":240,"primaryCompletion":62,"completion":67,"start":219,"enrollment":220,"conditions":241,"interventions":242},[75],[222],[63,224],{"intervention":58,"totalTrials":115,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":246,"activeCount":82},[],{"trials":248,"activeCount":82},[],{"trials":250,"activeCount":82},[],{"trials":252,"activeCount":82},[],{"trials":254,"activeCount":82},[],{"trials":256,"activeCount":115,"soonestReadout":57},[257],{"nctId":55,"briefTitle":56,"status":129,"phases":258,"primaryCompletion":57,"completion":57,"start":259,"enrollment":260,"conditions":261,"interventions":262},[],"2023-12-14",44,[20],[58],{"intervention":48,"totalTrials":115,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":266,"activeCount":82},[],{"trials":268,"activeCount":82},[],{"trials":270,"activeCount":82},[],{"trials":272,"activeCount":82},[],{"trials":274,"activeCount":82},[],{"trials":276,"activeCount":115,"soonestReadout":47},[277],{"nctId":45,"briefTitle":46,"status":129,"phases":278,"primaryCompletion":47,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":285},[75],"2026-07","2024-01-05",45,[283,284],"Septic Shock","Acute Kidney Injury",[48,286,287],"Vasopressin","Norepinephrine",{"intervention":286,"totalTrials":115,"cells":289},{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":296,"PHASE4":298,"NA":300},{"trials":291,"activeCount":82},[],{"trials":293,"activeCount":82},[],{"trials":295,"activeCount":82},[],{"trials":297,"activeCount":82},[],{"trials":299,"activeCount":82},[],{"trials":301,"activeCount":115,"soonestReadout":47},[302],{"nctId":45,"briefTitle":46,"status":129,"phases":303,"primaryCompletion":47,"completion":279,"start":280,"enrollment":281,"conditions":304,"interventions":305},[75],[283,284],[48,286,287],{"intervention":287,"totalTrials":115,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":309,"activeCount":82},[],{"trials":311,"activeCount":82},[],{"trials":313,"activeCount":82},[],{"trials":315,"activeCount":82},[],{"trials":317,"activeCount":82},[],{"trials":319,"activeCount":115,"soonestReadout":47},[320],{"nctId":45,"briefTitle":46,"status":129,"phases":321,"primaryCompletion":47,"completion":279,"start":280,"enrollment":281,"conditions":322,"interventions":323},[75],[283,284],[48,286,287],{"intervention":38,"totalTrials":115,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":327,"activeCount":82},[],{"trials":329,"activeCount":82},[],{"trials":331,"activeCount":82},[],{"trials":333,"activeCount":82},[],{"trials":335,"activeCount":82},[],{"trials":337,"activeCount":115,"soonestReadout":37},[338],{"nctId":35,"briefTitle":36,"status":129,"phases":339,"primaryCompletion":37,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":346},[75],"2026-04-08","2023-04-09",60,[344,345],"Focal Cortical Dysplasia","Epilepsy",[38],{"intervention":348,"totalTrials":115,"cells":349},"Posaconazole",{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":373},{"trials":351,"activeCount":82},[],{"trials":353,"activeCount":82},[],{"trials":355,"activeCount":82},[],{"trials":357,"activeCount":82},[],{"trials":359,"activeCount":82},[360],{"nctId":361,"briefTitle":362,"status":363,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":372},"NCT02875743","King's Invasive Aspergillosis Study II","COMPLETED",[74],"2018-10-31","2019-10-31","2016-12-07",120,[370,15,18,371],"Aplastic Anemia","Bone Marrow Transplantation",[348],{"trials":374,"activeCount":82},[],{"intervention":376,"totalTrials":115,"cells":377},"ZEPATIER 50Mg-100Mg",{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":400},{"trials":379,"activeCount":82},[],{"trials":381,"activeCount":82},[],{"trials":383,"activeCount":82},[],{"trials":385,"activeCount":82},[],{"trials":387,"activeCount":82},[388],{"nctId":389,"briefTitle":390,"status":391,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":399},"NCT03797066","ATTIC - Access To Treat in the Community","TERMINATED",[74],"2020-07-28","2020-11-30","2019-03-23",13,[398],"Hepatitis C, Chronic",[376],{"trials":401,"activeCount":82},[],{"intervention":403,"totalTrials":115,"cells":404},"Isoflurane, Sevoflurane or Desflurane",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":426},{"trials":406,"activeCount":82},[],{"trials":408,"activeCount":82},[],{"trials":410,"activeCount":82},[],{"trials":412,"activeCount":82},[],{"trials":414,"activeCount":82},[415],{"nctId":416,"briefTitle":417,"status":94,"phases":418,"primaryCompletion":419,"completion":420,"start":421,"enrollment":195,"conditions":422,"interventions":424},"NCT04039854","Comparison Between Propofol and Inhalational Anaesthetic Agents on Cardiovascular Outcomes Following Cardiac Surgery",[74],"2021-11-30","2022-01-31","2019-11-20",[423,27],"Coronary Heart Disease",[403,425],"Propofol",{"trials":427,"activeCount":82},[],{"intervention":425,"totalTrials":115,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":444},{"trials":431,"activeCount":82},[],{"trials":433,"activeCount":82},[],{"trials":435,"activeCount":82},[],{"trials":437,"activeCount":82},[],{"trials":439,"activeCount":82},[440],{"nctId":416,"briefTitle":417,"status":94,"phases":441,"primaryCompletion":419,"completion":420,"start":421,"enrollment":195,"conditions":442,"interventions":443},[74],[423,27],[403,425],{"trials":445,"activeCount":82},[],{"intervention":447,"totalTrials":115,"cells":448},"antibiotics",{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":471},{"trials":450,"activeCount":82},[],{"trials":452,"activeCount":82},[],{"trials":454,"activeCount":82},[],{"trials":456,"activeCount":82},[],{"trials":458,"activeCount":82},[459],{"nctId":460,"briefTitle":461,"status":94,"phases":462,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":470},"NCT01418456","Outcomes of Non-infected Diabetic Foot Ulcers With\u002FWithout Antibiotics",[74],"2012-02","2011-08",166,[467,468,469],"Diabetes","Foot Ulcers","Infection",[447],{"trials":472,"activeCount":82},[],{"intervention":474,"totalTrials":115,"cells":475},"Glibenclamide",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":495},{"trials":477,"activeCount":82},[],{"trials":479,"activeCount":82},[],{"trials":481,"activeCount":82},[],{"trials":483,"activeCount":82},[],{"trials":485,"activeCount":82},[486],{"nctId":487,"briefTitle":488,"status":94,"phases":489,"start":490,"enrollment":491,"conditions":492,"interventions":494},"NCT00472875","Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?",[74],"2007-05",10,[493],"Type 1 Diabetes Mellitus",[474],{"trials":496,"activeCount":82},[],{"intervention":498,"totalTrials":115,"cells":499},"CHOP-daclizumab",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":517},{"trials":501,"activeCount":82},[],{"trials":503,"activeCount":82},[],{"trials":505,"activeCount":82},[],{"trials":507,"activeCount":82},[],{"trials":509,"activeCount":82},[510],{"nctId":511,"briefTitle":512,"status":363,"phases":513,"conditions":514,"interventions":516},"NCT01418430","Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)",[74],[515],"HTLV-I Associated Adult T-cell Leukaemia\u002FLymphoma (ATLL)",[498],{"trials":518,"activeCount":82},[],{"intervention":520,"totalTrials":115,"cells":521},"Rifaximin-α",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":544},{"trials":523,"activeCount":82},[],{"trials":525,"activeCount":82},[],{"trials":527,"activeCount":82},[],{"trials":529,"activeCount":82},[],{"trials":531,"activeCount":82},[532],{"nctId":533,"briefTitle":534,"status":363,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":543},"NCT02019784","Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy",[74],"2016-06","2016-10","2015-01",38,[541,542],"Liver Cirrhosis","Hepatoencephalopathy, Early Fatal Progressive",[520],{"trials":545,"activeCount":82},[],{"intervention":547,"totalTrials":115,"cells":548},"Ferinject",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":572},{"trials":550,"activeCount":82},[],{"trials":552,"activeCount":82},[],{"trials":554,"activeCount":82},[],{"trials":556,"activeCount":82},[],{"trials":558,"activeCount":82},[559],{"nctId":560,"briefTitle":561,"status":363,"phases":562,"primaryCompletion":563,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":571},"NCT04862715","The Iron and Muscle Study",[74],"2021-12-21","2022-02-21","2019-04-26",75,[568,569,570],"CKD Stage 3","CKD Stage 4","Iron-deficiency",[547],{"trials":573,"activeCount":82},[],{"intervention":575,"totalTrials":115,"cells":576},"Paracetamol",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":598},{"trials":578,"activeCount":82},[],{"trials":580,"activeCount":82},[],{"trials":582,"activeCount":82},[],{"trials":584,"activeCount":82},[],{"trials":586,"activeCount":82},[587],{"nctId":588,"briefTitle":589,"status":94,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":597},"NCT04625608","Effect of Premedicant Oral Paracetamol on Gastric Volume and pH",[74],"2021-08","2021-12","2020-10-06",104,[596],"Fasting",[575],{"trials":599,"activeCount":82},[],{"intervention":601,"totalTrials":115,"cells":602},"Micronised progesterone",{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":622,"NA":624},{"trials":604,"activeCount":82},[],{"trials":606,"activeCount":82},[],{"trials":608,"activeCount":82},[],{"trials":610,"activeCount":82},[611],{"nctId":612,"briefTitle":613,"status":363,"phases":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":621},"NCT00422526","Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial",[73],"2006-11","2003-09",250,[619,620],"Preterm Birth","Pregnancy Trimester, Second",[601],{"trials":623,"activeCount":82},[],{"trials":625,"activeCount":82},[],{"intervention":627,"totalTrials":115,"cells":628},"C3F8 Gas",{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":635,"PHASE4":651,"NA":653},{"trials":630,"activeCount":82},[],{"trials":632,"activeCount":82},[],{"trials":634,"activeCount":82},[],{"trials":636,"activeCount":82},[637],{"nctId":638,"briefTitle":639,"status":363,"phases":640,"primaryCompletion":641,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":648},"NCT01835067","Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD",[72,73],"2019-11","2019-12","2014-09",55,[646,647],"Exudative Macular Degeneration","Retinal Hemorrhage",[649,627,650],"Ranibizumab","tPA",{"trials":652,"activeCount":82},[],{"trials":654,"activeCount":82},[],{"intervention":650,"totalTrials":115,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":669,"NA":671},{"trials":658,"activeCount":82},[],{"trials":660,"activeCount":82},[],{"trials":662,"activeCount":82},[],{"trials":664,"activeCount":82},[665],{"nctId":638,"briefTitle":639,"status":363,"phases":666,"primaryCompletion":641,"completion":642,"start":643,"enrollment":644,"conditions":667,"interventions":668},[72,73],[646,647],[649,627,650],{"trials":670,"activeCount":82},[],{"trials":672,"activeCount":82},[],{"intervention":674,"totalTrials":115,"cells":675},"prednisolone",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":694,"NA":696},{"trials":677,"activeCount":82},[],{"trials":679,"activeCount":82},[],{"trials":681,"activeCount":82},[],{"trials":683,"activeCount":82},[684],{"nctId":685,"briefTitle":686,"status":94,"phases":687,"completion":688,"start":689,"enrollment":690,"conditions":691,"interventions":693},"NCT00539565","RCT of Steroids Following Kasai Portoenterostomy for Biliary Atresia.",[73],"2008-09","2000-01",100,[692],"Biliary Atresia",[674],{"trials":695,"activeCount":82},[],{"trials":697,"activeCount":82},[],{"intervention":699,"totalTrials":115,"cells":700},"0.9% Sodium Chloride",{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":720,"NA":722},{"trials":702,"activeCount":82},[],{"trials":704,"activeCount":82},[],{"trials":706,"activeCount":82},[],{"trials":708,"activeCount":82},[709],{"nctId":710,"briefTitle":711,"status":363,"phases":712,"primaryCompletion":713,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":719},"NCT01030770","Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:",[72,73],"2015-12","2016-05","2010-07",25,[718],"Diabetes Complications",[649,699],{"trials":721,"activeCount":82},[],{"trials":723,"activeCount":82},[],{"intervention":725,"totalTrials":115,"cells":726},"0.5 mg ranibizumab",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":745,"NA":747},{"trials":728,"activeCount":82},[],{"trials":730,"activeCount":82},[],{"trials":732,"activeCount":82},[],{"trials":734,"activeCount":82},[735],{"nctId":736,"briefTitle":737,"status":363,"phases":738,"primaryCompletion":592,"completion":739,"start":740,"enrollment":741,"conditions":742,"interventions":744},"NCT02243878","Stereotactic Radiotherapy for Wet AMD (STAR)",[73],"2024-04","2014-12",411,[743],"Neovascular (Wet) Age-related Macular Degeneration (AMD)",[725],{"trials":746,"activeCount":82},[],{"trials":748,"activeCount":82},[],{"intervention":750,"totalTrials":78,"cells":751},"Fludarabine",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":753,"activeCount":82},[],{"trials":755,"activeCount":82},[],{"trials":757,"activeCount":82},[758,769],{"nctId":759,"briefTitle":760,"status":391,"phases":761,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":765,"interventions":766},"NCT00915811","Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin",[72],"2011-06","2007-06",20,[18,15],[750,767,768],"Busulphan","Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme",{"nctId":770,"briefTitle":771,"status":391,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":8,"conditions":775,"interventions":780},"NCT00916045","Pilot Study of Unrelated Cord Blood Transplantation",[72],"2012-03","2009-09",[15,18,776,777,778,779],"Leukemia, Lymphoblastic, Acute","Lymphoma, Non-Hodgkin","Hodgkin Disease","Chronic Lymphocytic Leukemia",[781,750,782,783,784,785,750,786,783,784,785,750,787,783,784,785],"Thiotepa","Intravenous busulphan","Thymoglobulin","Ciclosporin","Mycophenolate mofetil","Cyclophosphamide","Melphalan",{"trials":789,"activeCount":82},[],{"trials":791,"activeCount":82},[],{"trials":793,"activeCount":82},[],{"intervention":795,"totalTrials":78,"cells":796},"Lenalidomide",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":798,"activeCount":82},[],{"trials":800,"activeCount":82},[],{"trials":802,"activeCount":82},[803,814],{"nctId":804,"briefTitle":805,"status":363,"phases":806,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":812},"NCT00915408","A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma",[71,72],"2014-03","2006-09",32,[811],"Multiple Myeloma",[795,813,786],"Dexamethasone",{"nctId":815,"briefTitle":816,"status":363,"phases":817,"primaryCompletion":714,"completion":714,"start":818,"enrollment":819,"conditions":820,"interventions":821},"NCT00874978","The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality",[72],"2005-01",36,[18],[822],"lenalidomide",{"trials":824,"activeCount":82},[],{"trials":826,"activeCount":82},[],{"trials":828,"activeCount":82},[],{"intervention":786,"totalTrials":78,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":832,"activeCount":82},[],{"trials":834,"activeCount":82},[],{"trials":836,"activeCount":82},[837,841],{"nctId":804,"briefTitle":805,"status":363,"phases":838,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":839,"interventions":840},[71,72],[811],[795,813,786],{"nctId":770,"briefTitle":771,"status":391,"phases":842,"primaryCompletion":773,"completion":773,"start":774,"enrollment":8,"conditions":843,"interventions":844},[72],[15,18,776,777,778,779],[781,750,782,783,784,785,750,786,783,784,785,750,787,783,784,785],{"trials":846,"activeCount":82},[],{"trials":848,"activeCount":82},[],{"trials":850,"activeCount":82},[],{"intervention":767,"totalTrials":115,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":863,"PHASE4":865,"NA":867},{"trials":854,"activeCount":82},[],{"trials":856,"activeCount":82},[],{"trials":858,"activeCount":82},[859],{"nctId":759,"briefTitle":760,"status":391,"phases":860,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":861,"interventions":862},[72],[18,15],[750,767,768],{"trials":864,"activeCount":82},[],{"trials":866,"activeCount":82},[],{"trials":868,"activeCount":82},[],{"intervention":768,"totalTrials":115,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":881,"PHASE4":883,"NA":885},{"trials":872,"activeCount":82},[],{"trials":874,"activeCount":82},[],{"trials":876,"activeCount":82},[877],{"nctId":759,"briefTitle":760,"status":391,"phases":878,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":879,"interventions":880},[72],[18,15],[750,767,768],{"trials":882,"activeCount":82},[],{"trials":884,"activeCount":82},[],{"trials":886,"activeCount":82},[],{"intervention":888,"totalTrials":115,"cells":889},"metronidazole, clarithromycin, ciprofloxacin and lansoprazole",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":906,"PHASE4":908,"NA":910},{"trials":891,"activeCount":82},[],{"trials":893,"activeCount":82},[],{"trials":895,"activeCount":82},[896],{"nctId":897,"briefTitle":898,"status":363,"phases":899,"primaryCompletion":538,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":905},"NCT01279252","CLL Empirical Antibiotic Regimen",[72],"2016-03","2011-07",71,[904],"Chronic Lymphocytic Leukaemia (CLL)",[888],{"trials":907,"activeCount":82},[],{"trials":909,"activeCount":82},[],{"trials":911,"activeCount":82},[],{"intervention":913,"totalTrials":115,"cells":914},"HMB002",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":916,"activeCount":82},[],{"trials":918,"activeCount":82},[],{"trials":920,"activeCount":82},[921],{"nctId":922,"briefTitle":923,"status":94,"phases":924,"primaryCompletion":925,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":931},"NCT05491135","Hepatocyte Microbeads for Acute Liver Failure",[71,72],"2025-11","2026-05","2022-09",17,[930],"Acute Liver Failure",[913],{"trials":933,"activeCount":82},[],{"trials":935,"activeCount":82},[],{"trials":937,"activeCount":82},[],{"intervention":813,"totalTrials":115,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":941,"activeCount":82},[],{"trials":943,"activeCount":82},[],{"trials":945,"activeCount":82},[946],{"nctId":804,"briefTitle":805,"status":363,"phases":947,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":948,"interventions":949},[71,72],[811],[795,813,786],{"trials":951,"activeCount":82},[],{"trials":953,"activeCount":82},[],{"trials":955,"activeCount":82},[],{"intervention":957,"totalTrials":115,"cells":958},"Lutathera",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":960,"activeCount":82},[],{"trials":962,"activeCount":82},[],{"trials":964,"activeCount":82},[965],{"nctId":966,"briefTitle":967,"status":94,"phases":968,"primaryCompletion":969,"completion":97,"start":970,"enrollment":764,"conditions":971,"interventions":975},"NCT04039516","Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy",[72],"2024-11","2020-10",[972,973,974],"Carcinoid Heart Disease","Carcinoid Syndrome","Carcinoid Tumor",[957],{"trials":977,"activeCount":82},[],{"trials":979,"activeCount":82},[],{"trials":981,"activeCount":82},[],{"intervention":781,"totalTrials":115,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":985,"activeCount":82},[],{"trials":987,"activeCount":82},[],{"trials":989,"activeCount":82},[990],{"nctId":770,"briefTitle":771,"status":391,"phases":991,"primaryCompletion":773,"completion":773,"start":774,"enrollment":8,"conditions":992,"interventions":993},[72],[15,18,776,777,778,779],[781,750,782,783,784,785,750,786,783,784,785,750,787,783,784,785],{"trials":995,"activeCount":82},[],{"trials":997,"activeCount":82},[],{"trials":999,"activeCount":82},[],{"intervention":782,"totalTrials":115,"cells":1001},{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":1003,"activeCount":82},[],{"trials":1005,"activeCount":82},[],{"trials":1007,"activeCount":82},[1008],{"nctId":770,"briefTitle":771,"status":391,"phases":1009,"primaryCompletion":773,"completion":773,"start":774,"enrollment":8,"conditions":1010,"interventions":1011},[72],[15,18,776,777,778,779],[781,750,782,783,784,785,750,786,783,784,785,750,787,783,784,785],{"trials":1013,"activeCount":82},[],{"trials":1015,"activeCount":82},[],{"trials":1017,"activeCount":82},[],{"intervention":783,"totalTrials":115,"cells":1019},{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1021,"activeCount":82},[],{"trials":1023,"activeCount":82},[],{"trials":1025,"activeCount":82},[1026],{"nctId":770,"briefTitle":771,"status":391,"phases":1027,"primaryCompletion":773,"completion":773,"start":774,"enrollment":8,"conditions":1028,"interventions":1029},[72],[15,18,776,777,778,779],[781,750,782,783,784,785,750,786,783,784,785,750,787,783,784,785],{"trials":1031,"activeCount":82},[],{"trials":1033,"activeCount":82},[],{"trials":1035,"activeCount":82},[],{"intervention":784,"totalTrials":115,"cells":1037},{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1039,"activeCount":82},[],{"trials":1041,"activeCount":82},[],{"trials":1043,"activeCount":82},[1044],{"nctId":770,"briefTitle":771,"status":391,"phases":1045,"primaryCompletion":773,"completion":773,"start":774,"enrollment":8,"conditions":1046,"interventions":1047},[72],[15,18,776,777,778,779],[781,750,782,783,784,785,750,786,783,784,785,750,787,783,784,785],{"trials":1049,"activeCount":82},[],{"trials":1051,"activeCount":82},[],{"trials":1053,"activeCount":82},[],{"intervention":785,"totalTrials":115,"cells":1055},{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1057,"activeCount":82},[],{"trials":1059,"activeCount":82},[],{"trials":1061,"activeCount":82},[1062],{"nctId":770,"briefTitle":771,"status":391,"phases":1063,"primaryCompletion":773,"completion":773,"start":774,"enrollment":8,"conditions":1064,"interventions":1065},[72],[15,18,776,777,778,779],[781,750,782,783,784,785,750,786,783,784,785,750,787,783,784,785],{"trials":1067,"activeCount":82},[],{"trials":1069,"activeCount":82},[],{"trials":1071,"activeCount":82},[],{"intervention":787,"totalTrials":115,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1075,"activeCount":82},[],{"trials":1077,"activeCount":82},[],{"trials":1079,"activeCount":82},[1080],{"nctId":770,"briefTitle":771,"status":391,"phases":1081,"primaryCompletion":773,"completion":773,"start":774,"enrollment":8,"conditions":1082,"interventions":1083},[72],[15,18,776,777,778,779],[781,750,782,783,784,785,750,786,783,784,785,750,787,783,784,785],{"trials":1085,"activeCount":82},[],{"trials":1087,"activeCount":82},[],{"trials":1089,"activeCount":82},[],{"intervention":1091,"totalTrials":115,"cells":1092},"RFUSIN2-AML1",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1108,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1094,"activeCount":82},[],{"trials":1096,"activeCount":82},[1097],{"nctId":1098,"briefTitle":1099,"status":94,"phases":1100,"primaryCompletion":1101,"completion":463,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1105},"NCT00718250","Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2",[71],"2011-05","2008-05",24,[15],[1091,1106,1107,1107],"Donor leukocyte","RFUSIN2-AML1 and donor leukocyte",{"trials":1109,"activeCount":82},[],{"trials":1111,"activeCount":82},[],{"trials":1113,"activeCount":82},[],{"trials":1115,"activeCount":82},[],{"intervention":1106,"totalTrials":115,"cells":1117},{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1126,"PHASE3":1128,"PHASE4":1130,"NA":1132},{"trials":1119,"activeCount":82},[],{"trials":1121,"activeCount":82},[1122],{"nctId":1098,"briefTitle":1099,"status":94,"phases":1123,"primaryCompletion":1101,"completion":463,"start":1102,"enrollment":1103,"conditions":1124,"interventions":1125},[71],[15],[1091,1106,1107,1107],{"trials":1127,"activeCount":82},[],{"trials":1129,"activeCount":82},[],{"trials":1131,"activeCount":82},[],{"trials":1133,"activeCount":82},[],{"intervention":1107,"totalTrials":115,"cells":1135},{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1144,"PHASE3":1146,"PHASE4":1148,"NA":1150},{"trials":1137,"activeCount":82},[],{"trials":1139,"activeCount":82},[1140],{"nctId":1098,"briefTitle":1099,"status":94,"phases":1141,"primaryCompletion":1101,"completion":463,"start":1102,"enrollment":1103,"conditions":1142,"interventions":1143},[71],[15],[1091,1106,1107,1107],{"trials":1145,"activeCount":82},[],{"trials":1147,"activeCount":82},[],{"trials":1149,"activeCount":82},[],{"trials":1151,"activeCount":82},[],{"intervention":649,"totalTrials":25,"cells":1153},{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1170,"NA":1183},{"trials":1155,"activeCount":82},[],{"trials":1157,"activeCount":82},[],{"trials":1159,"activeCount":82},[],{"trials":1161,"activeCount":82},[1162,1166],{"nctId":638,"briefTitle":639,"status":363,"phases":1163,"primaryCompletion":641,"completion":642,"start":643,"enrollment":644,"conditions":1164,"interventions":1165},[72,73],[646,647],[649,627,650],{"nctId":710,"briefTitle":711,"status":363,"phases":1167,"primaryCompletion":713,"completion":714,"start":715,"enrollment":716,"conditions":1168,"interventions":1169},[72,73],[718],[649,699],{"trials":1171,"activeCount":82},[1172],{"nctId":1173,"briefTitle":1174,"status":363,"phases":1175,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1180,"interventions":1182},"NCT01006538","Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)",[74],"2015-03","2016-12","2009-11",363,[1181],"Macular Degeneration",[649],{"trials":1184,"activeCount":82},[1185],{"nctId":1186,"briefTitle":1187,"status":363,"phases":1188,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1195},"NCT02174211","A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.",[75],"2020-11","2020-12","2014-06",59,[1194],"Age Related Macular Degeneration",[649,1196],"Aflibercept",{"intervention":1196,"totalTrials":115,"cells":1198},{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1200,"activeCount":82},[],{"trials":1202,"activeCount":82},[],{"trials":1204,"activeCount":82},[],{"trials":1206,"activeCount":82},[],{"trials":1208,"activeCount":82},[],{"trials":1210,"activeCount":82},[1211],{"nctId":1186,"briefTitle":1187,"status":363,"phases":1212,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":1213,"interventions":1214},[75],[1194],[649,1196],{"intervention":1216,"totalTrials":115,"cells":1217},"Mepolizumab",{"EARLY_PHASE1":1218,"PHASE1":1220,"PHASE2":1222,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1219,"activeCount":82},[],{"trials":1221,"activeCount":82},[],{"trials":1223,"activeCount":82},[],{"trials":1225,"activeCount":82},[],{"trials":1227,"activeCount":82},[],{"trials":1229,"activeCount":82},[1230],{"nctId":1231,"briefTitle":1232,"status":94,"phases":1233,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1240},"NCT05139381","Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With Mepolizumab",[],"2026-03","2026-03-12","2022-03-02",148,[1239],"Asthma in Children",[1216],{"intervention":1242,"totalTrials":115,"cells":1243},"250 ML NaCl 4.5 MG\u002FML",{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1250,"PHASE4":1252,"NA":1254},{"trials":1245,"activeCount":82},[],{"trials":1247,"activeCount":82},[],{"trials":1249,"activeCount":82},[],{"trials":1251,"activeCount":82},[],{"trials":1253,"activeCount":82},[],{"trials":1255,"activeCount":82},[1256],{"nctId":1257,"briefTitle":1258,"status":94,"phases":1259,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":1264,"interventions":1266},"NCT06158555","Targeted Perfusion Based Haemodynamic Management in Critically Ill Patients Using Urethral Perfusion",[75],"2024-06-01","2024-12-01","2023-04-01",30,[1265],"Critically Ill",[1242],{"intervention":1268,"totalTrials":115,"cells":1269},"Tolvaptan",{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1271,"activeCount":82},[],{"trials":1273,"activeCount":82},[],{"trials":1275,"activeCount":82},[],{"trials":1277,"activeCount":82},[],{"trials":1279,"activeCount":82},[],{"trials":1281,"activeCount":82},[1282],{"nctId":1283,"briefTitle":1284,"status":94,"phases":1285,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":1289,"conditions":1290,"interventions":1293},"NCT06171100","Low-dose Tolvaptan for Inpatient Hyponatraemia.",[],"2024-06-30","2024-12-30","2024-03-15",180,[1291,1292],"Hyponatremia","SIADH",[1268],{"intervention":1295,"totalTrials":115,"cells":1296},"Mitotane",{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1298,"activeCount":82},[],{"trials":1300,"activeCount":82},[],{"trials":1302,"activeCount":82},[],{"trials":1304,"activeCount":82},[],{"trials":1306,"activeCount":82},[],{"trials":1308,"activeCount":82},[1309],{"nctId":1310,"briefTitle":1311,"status":363,"phases":1312,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1319},"NCT05344027","The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma",[],"2023-01-30","2023-03-01","2022-04-11",35,[1318],"Adrenocortical Carcinoma",[1295]]